Pharma companies directory 2026

    Pharmaceutical Companies in Kenya

    Nairobi’s Industrial Area and Kikuyu now host the plants that fill a growing share of Kenyan blister packs, yet KEMSA tenders and Social Health Authority reimbursement still decide which factory or importer actually gets paid.

    The Pharmacy and Poisons Board, operating under Cap 244 and the PRIMS digital file, is the marketing-authorisation holder’s first counterpart: every finished medicine, whether pressed in Kikuyu or landed at Mombasa, needs a PPB registration and a licensed local entity. Universal Corporation, Cosmos, Dawa and Lab & Allied have turned that rule into an industrial advantage, supplying tablets, syrups and some injectables that county hospitals and private pharmacies now treat as default generics. Multinational affiliates — GSK Kenya, Novartis and Pfizer — kept Nairobi commercial teams after several peers switched to agency models, because Kenya is the detailing and regulatory hub for a wider East African Community book. Public volume concentrates at the Kenya Medical Supplies Authority, whose framework contracts feed county health departments; when KEMSA is late or underfunded, counties buy from private wholesalers in Industrial Area and along Mombasa Road, and Indian-origin traders fill the gap. The Social Health Authority, which replaced the National Hospital Insurance Fund, is rewriting the reimbursed list, and a brand that is not on the SHA formulary will struggle in the expanding outpatient packages. This directory is the account map BioNixus uses when a client asks who holds share in a therapy class in Nairobi, Mombasa, Kisumu or Eldoret.

    Updated September 2026 · Pharmacy and Poisons Board (PPB) — registered products, licensed manufacturers and PRIMS premise records as of September 2026 · 19 named accounts

    Request a proposal for KenyaBrowse the 19 companies

    ~$0.8bn

    Kenya pharmaceutical market, 2024 commercial estimates (about USD 0.77–0.80bn)

    37+

    Licensed pharmaceutical manufacturers cited in the national local-manufacturing strategy

    47

    County governments that buy from KEMSA and, when stocks fail, from private wholesalers

    17.8m

    People registered with the Social Health Authority by January 2025 after NHIF closed

    Named accounts

    Top pharmaceutical companies in Kenya

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Pharmacy and Poisons Board (PPB) — registered products, licensed manufacturers and PRIMS premise records (as of 2026-09-04).
    #CompanyHQ
    01Universal CorporationKikuyu
    02Cosmos LimitedNairobi
    03Dawa LimitedNairobi
    04Lab & AlliedNairobi
    05Regal PharmaceuticalsNairobi
    06Beta HealthcareNairobi
    07Elys Chemical IndustriesNairobi
    08Biodeal LaboratoriesNairobi
    09GSK KenyaNairobi
    10Novartis KenyaNairobi
    11Pfizer KenyaNairobi
    12Sanofi KenyaNairobi
    13Cipla KenyaNairobi
    14Mission for Essential Drugs and Supplies (MEDS)Nairobi
    15Social Health Authority (SHA)Nairobi
    16SurgipharmNairobi
    17Harleys LimitedNairobi
    18Kenya Medical Supplies Authority (KEMSA)Nairobi
    19Pharmacy and Poisons Board (PPB)Nairobi

    Primary research

    These are the pharmaceutical companies accounts we study in Kenya

    Need account-level or SKU-level data for a brand in Kenya? BioNixus runs primary fieldwork — brand vs competitors, including the channels a dashboard averages away. Proposal ready within 48 hours of a brief.

    Planning research in Kenya?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Kenya (2026)

    How the market is structured

    How pharmaceutical companies reach Kenyan pharmacies and county hospitals

    A PPB registration sits with a Kenyan marketing authorisation holder — a local plant, a multinational affiliate, or an importer such as Surgipharm or Harleys that files on behalf of a foreign principal. Goods then move through two pipes. KEMSA’s framework agreements and last-mile delivery are supposed to stock county hospitals and primary facilities; in practice, delayed exchequer releases and quality disputes push county pharmacists toward Industrial Area wholesalers, so a manufacturer that only wins the KEMSA paper and never details the counties will still lose volume. Private retail is fragmented: a few organised groups in Nairobi and Mombasa sit beside thousands of independent pharmacies whose owners buy from Lab & Allied, Cosmos, Dawa and a thicket of Indian-origin distributors. Medical representatives concentrate on consultants at Kenyatta National Hospital, Moi Teaching and Referral, Aga Khan and the larger private hospitals, while pharmaceutical technologists behind the counter decide substitution for most cash-pay acute scripts. SHA outpatient and chronic packages are beginning to pull volume toward listed generics with reliable supply records, which favours plants that can invoice consistently in shillings and still import APIs when the dollar is tight. Cross-border, the same Nairobi affiliates often hold the EAC reference pack for Uganda, Rwanda and Tanzania, so a Kenyan registration delay now holds up a regional launch calendar.

    Local

    Kikuyu and Industrial Area manufacturers — Universal, Cosmos, Dawa, Lab & Allied, Regal, Elys, Biodeal — that press essential generics and still invoice county hospitals when KEMSA shelves are empty.

    • Universal Corporation
    • Cosmos Limited
    • Dawa Limited
    • Lab & Allied
    • Regal Pharmaceuticals
    • Elys Chemical Industries
    • Biodeal Laboratories

    Multinational

    GSK, Novartis, Pfizer, Sanofi and Cipla affiliates that kept Nairobi medical teams and treat Kenya as the East African registration, pharmacovigilance and key-opinion-leader hub.

    • GSK Kenya
    • Novartis Kenya
    • Pfizer Kenya
    • Sanofi Kenya
    • Cipla Kenya

    Regional

    East African and South Asian groups such as Beta Healthcare that use Nairobi trade terms and PPB files as the lead dossier for Uganda, Rwanda and Tanzania.

    • Beta Healthcare

    Distributors & importers

    Surgipharm and Harleys as importer-wholesalers, MEDS as the mission buyer, KEMSA and SHA as public demand, and the Pharmacy and Poisons Board as the licence that every other actor depends on.

    • Mission for Essential Drugs and Supplies (MEDS)
    • Social Health Authority (SHA)
    • Surgipharm
    • Harleys Limited
    • Kenya Medical Supplies Authority (KEMSA)
    • Pharmacy and Poisons Board (PPB)

    What is moving

    What is moving the pharmaceutical market in Kenya

    Social Health Authority outpatient packages

    SHA reimbursement is replacing NHIF rules and pulling cash-pay acute scripts toward listed generics with clean supply records, which rewards plants that can invoice in shillings without breaking API import cover.

    County buying when KEMSA fill rates slip

    Devolved health budgets let county pharmacists buy locally whenever the national warehouse is late, so manufacturers with vans on Mombasa Road now win volume that used to wait for a KEMSA call-off.

    East African Community hub status

    A Nairobi registration and medical organisation still unlocks Uganda, Rwanda and Tanzania detailing calendars, which is why several innovators refused to collapse Kenya into a pure distributor model.

    PPB digital files and WHO-aligned inspections

    PRIMS submissions and tighter GMP inspections are raising the cost of staying licensed, which favours the larger Kikuyu and Industrial Area plants over traders who only held paper registrations.

    BioNixus fieldwork

    How BioNixus studies pharmaceutical companies in Kenya

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Kenya:
    • KEMSA framework-award reconstruction for antimalarials, antibiotics and maternal-health commodities, including county-level stock-out workarounds.
    • SHA formulary interviews with scheme pharmacists on which local generics qualify for the new outpatient and chronic packages.
    • Independent-pharmacy purchase audits in Nairobi, Mombasa and Kisumu comparing Cosmos, Dawa, Lab & Allied and Indian-import share.
    • Consultant detailing maps at Kenyatta National Hospital, Moi Teaching and Referral and Aga Khan University Hospital for specialty and vaccine brands.

    Questions

    Frequently Asked Questions

    What does a PPB marketing authorisation actually permit in Kenya?

    It allows a named Kenyan entity to import or manufacture that pack and to sell it through licensed premises. Without the PPB file, KEMSA will not award, SHA will not reimburse, and a county pharmacist cannot legally issue the product.

    Which local plants show up most often in Kenyan private pharmacies?

    Cosmos, Dawa, Lab & Allied, Universal Corporation and Regal occupy the widest independent-pharmacy bays. Universal is also the name that appears most often when a buyer asks for a WHO-prequalified local pack.

    Why do county governments buy outside KEMSA?

    When framework stock is late, quality-queried or underfunded, county pharmacists are authorised to purchase from licensed private wholesalers. That leakage is now a planned channel, not an exception, for several essential classes.

    Did GSK, Novartis and Pfizer keep real Nairobi affiliates?

    Yes. Unlike some peers that switched to agency models, those three still run Kenyan commercial and medical teams and use Nairobi as the East African hub for registration and consultant detailing.

    How does BioNixus field pharmaceutical-company work in Kenya?

    KEMSA award mapping by molecule, SHA formulary interviews, purchase audits in Industrial Area wholesale and independent pharmacies, and prescriber work at Kenyatta, Moi Teaching and Referral, Aga Khan Nairobi and Coast General.

    Does placement on this Kenyan list mean market rank?

    No. Selection follows PPB licences, KEMSA awards and accounts that recur in BioNixus Nairobi and county projects. Order is editorial, not a share table.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Kenya. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Pharmacy and Poisons Board (PPB) — registered products, licensed manufacturers and PRIMS premise records, consulted 2026-09-04. Company classification (Local / MNC / Regional / distributors & importers) reflects ownership and role in Kenya, not size.

    • Pharmacy and Poisons Board PRIMS and licensed-manufacturer notices; Pharmacy and Poisons Act Cap 244
    • Kenya Medical Supplies Authority framework-contract awards and county fill-rate reports, 2024–2026
    • Social Health Authority benefit-package and formulary communications replacing NHIF schedules
    • BioNixus Kenya county-hospital, Industrial Area wholesale and teaching-hospital fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need brand and competitor data in Kenya?

    Physician, pharmacist and payer fieldwork on the accounts above — prescription share, formulary position and tender exposure. Proposal within 48 hours.

    Planning research in Kenya?

    Primary research, market access & HEOR. Proposals within 48 hours.